LINEZAN SOLUTION FOR INFUSION 2MG/ML

ANFARM HELLAS S.A. (GREECE)🇸🇬 Health Sciences Authority

Approval Date: Feb 16, 2024
Approval ID: a0e114b7fe20c9d9
Company: ANFARM HELLAS S.A. (GREECE)
Type: Therapeutic

Approval Details

Approval Id: a0e114b7fe20c9d9
Drug Name: LINEZAN SOLUTION FOR INFUSION 2MG/ML
Product Name: LINEZAN SOLUTION FOR INFUSION 2MG/ML
Approval Number: SIN16950P
Approval Date: 2024-02-16
Registrant: GOLDPLUS UNIVERSAL PTE LTD
Licence Holder: GOLDPLUS UNIVERSAL PTE LTD
Drug Type: Therapeutic
Forensic Classification: PRESCRIPTION ONLY MEDICINES
Dosage Form: INFUSION, SOLUTION
Dosage: 4.2 Posology and method of administration Patients whose therapy is started with linezolid injection may be switched to linezolid tablets or linezolid for oral suspension, with no dosage adjustment. Linezolid oral dosage forms are unavailable in this brand but are available in other brands. Where oral administration is required, refer to the specific product information of these brands for the relevant dosage and administration instructions. <img src="/TGIF/Linezan-Table1.png" alt="Linezan Dosage Table 1" /> Elderly patients: No dose adjustment is required. Patients with renal insufficiency: No dose adjustment is required (see section 5.2 Pharmacokinetic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Patients with severe renal insufficiency (i.e. CLCR < 30 ml/min): No dose adjustment is required. Due to the unknown clinical significance of higher exposure (up to 10 fold) to the two primary metabolites of linezolid in patients with severe renal insufficiency, linezolid should be used with special caution in these patients and only when the anticipated benefit is considered to outweigh the theoretical risk. As approximately 30% of a linezolid dose is removed during 3 hours of haemodialysis, linezolid should be given after dialysis in patients receiving such treatment. The primary metabolites of linezolid are removed to some extent by haemodialysis, but the concentrations of these metabolites are still very considerably higher following dialysis than those observed in patients with normal renal function or mild to moderate renal insufficiency. Therefore, linezolid should be used with special caution in patients with severe renal insufficiency who are undergoing dialysis and only when the anticipated benefit is considered to outweigh the theoretical risk. To date, there is no experience of linezolid administration to patients undergoing continuous ambulatory peritoneal dialysis (CAPD) or alternative treatments for renal failure (other than haemodialysis). Patients with hepatic insufficiency: No dose adjustment is required. However, there are limited clinical data and it is recommended that linezolid should be used in such patients only when the anticipated benefit is considered to outweigh the theoretical risk (see section 5.2 Pharmacokinetic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Paediatric population: Recommended dosages for pediatric patients, please refer to the table above. Linezolid Injection Administer linezolid injection by intravenous infusion over a period of 30 to 120 minutes. Do not use the intravenous infusion bag in series connections. Do not introduce additives into the intravenous solution. If linezolid injection is to be given concomitantly with another drug, each drug should be given separately, in accordance with the recommended dosage and route of administration for each product. Linezolid injection was physically incompatible with the following drugs when combined in simulated Y-site administration: amphotericin B, chlorpromazine HCl, diazepam, pentamidine isethionate, phenytoin sodium, erythromycin lactobionate and trimethoprim-sulfamethoxazole. Linezolid injection was chemically incompatible when combined with ceftriaxone sodium. Compatible Infusion Solutions: 5% Glucose Injection 0.9% Sodium Chloride Injection Lactated Ringer’s Injection
Route Of Administration: INTRAVENOUS
Indication Info: 4.1 Therapeutic indications Linezolid is indicated for the treatment of adults and adolescents (12 years and older) and pediatric patients (birth through 11 years of age) with the following infections caused by susceptible strains of Gram-positive bacteria only. Linezolid is not indicated for the treatment of Gram-negative infections. Specific Gram-negative therapy is required if a concomitant Gram-negative pathogen is documented or suspected (see sections 4.4 Special warnings and precautions for use and 5.1 Pharmacodynamic properties – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Community-acquired pneumonia caused by Streptococcus pneumoniae (penicillin-sensitive strains only), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-sensitive strains only). Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-sensitive and methicillin-resistant strains) or Streptococcus pneumoniae (penicillin-sensitive strains only). Complicated skin and soft tissue infections, caused by Staphylococcus aureus (methicillin-sensitive and methicillin-resistant strains), Streptococcus pyogenes or Streptococcus agalactiae. Vancomycin-resistant Enterococcus faecium infections including cases with concurrent bacteremia. Linezolid should not be initiated as a first line therapy for community acquired pneumonia but may be considered if resistant strains are suspected or proven or in presence of drug allergy.
Contraindications: 4.3 Contraindications Linezolid is contraindicated in patients who have previously demonstrated hypersensitivity to linezolid or any of the other product components. Monoamine Oxidase Inhibitors Linezolid should not be used in patients taking any medicinal product which inhibits monoamine oxidases A or B (e.g., phenelzine, isocarboxazid) or within two weeks of taking any such medicinal product. Potential Interactions Producing Elevation of Blood Pressure Unless patients are monitored for potential increases in blood pressure, linezolid should not be administered to patients with uncontrolled hypertension, pheochromocytoma, thyrotoxicosis and/or patients taking any of the following types of medications: directly and indirectly acting sympathomimetic agents (e.g., pseudoephedrine, phenylpropanolamine), vasopressive agents (e.g., epinephrine, norepinephrine), dopaminergic agents (e.g., dopamine, dobutamine) (see section 4.5 Interaction with other medicinal products and other forms of interaction – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Potential Serotonergic Interactions Unless patients are carefully observed for signs and/or symptoms of serotonin syndrome, linezolid should not be administered to patients with carcinoid syndrome and/or patients taking any of the following medications: serotonin re-uptake inhibitors, tricyclic antidepressants, serotonin 5-HT1 receptor agonists (triptans), meperidine or buspirone (see section 4.5 Interaction with other medicinal products and other forms of interaction – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).
Atc Code: J01XX08
Atc Item Name: linezolid
Pharma Manufacturer Name: GOLDPLUS UNIVERSAL PTE LTD

Active Ingredients

Linezolid

2 mg/ml

Linezolid

2 mg/ml

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Feb 16, 2024

Approval ID

a0e114b7fe20c9d9

Type

Therapeutic

Back to HSA Approvals